Drug_Name,STUDYID,YEAR,Country,Dataset,Patient_Count,Median_Age,Female_Percentage,Male_Percentage,Median_BMI,Smoking_History_Yes_Percentage,Total_ADL_Independence_Percentage,LHRH_Use_Percentage,Tumor_Stage_T1_Percentage,Tumor_Stage_T2_Percentage,Tumor_Stage_T3_Percentage,Tumor_Stage_T4_Percentage,Nodal_Stage_N0_Percentage,Nodal_Stage_N1_Percentage,Nodal_Stage_N2_Percentage,Nodal_Stage_N3_Percentage,Stage_I_Percentage,Stage_II_Percentage,Stage_III_Percentage,Diabetes_Mellitus_Percentage,Congestive_Heart_Failure_Percentage,Stroke_Percentage,Atrial_Fibrillation_Percentage,Myocardial_Infarction_Percentage,Neoadjuvant_Chemotherapy_Received_Percentage,Adjuvant_Chemotherapy_Received_Percentage,Postoperative_RT_Received_Percentage,Common_Neoadjuvant_Regimen_1,Common_Neoadjuvant_Regimen_2,Common_Adjuvant_Regimen_1,Common_Adjuvant_Regimen_2,Tamoxifen_Percentage,Letrozole_Percentage,Anastrozole_Percentage,Antidiarrheal_Agent_Probiotics_Percentage,Antiemetic_Agent_Percentage,Painkiller_Antipyretic_Percentage,Beds_Less_Than_200_Percentage,Beds_200_To_499_Percentage,Beds_Greater_Or_Equal_To_500_Percentage,Designated_Cancer_Hospital_Percentage,Months_Between_Surgery_And_Index_Date
Thalidomide,ThalStudy001,2021,USA,MDV,350,68,42,58,27.5,32,78,12,15,35,30,20,45,30,15,10,20,35,45,18,8,5,10,7,25,40,55,Docetaxel + Cisplatin + 5-FU,Paclitaxel + Carboplatin,Capecitabine,Cyclophosphamide + Doxorubicin,15,10,8,22,65,70,15,45,40,60,2
Thalidomide,ThalStudy002,2022,Canada,Claim Database,420,72,38,62,28.1,28,75,15,12,38,32,18,48,28,14,10,18,38,44,20,10,6,12,8,22,42,52,Docetaxel + Cisplatin + 5-FU,Paclitaxel + Carboplatin,Capecitabine,Cyclophosphamide + Doxorubicin,12,13,5,25,62,68,18,42,40,58,3
Thalidomide,ThalStudy003,2023,UK,MDV,280,65,45,55,26.8,35,80,10,18,32,35,15,50,25,15,10,22,32,46,16,7,4,9,6,28,38,58,Docetaxel + Cisplatin + 5-FU,Paclitaxel + Carboplatin,Capecitabine,Cyclophosphamide + Doxorubicin,18,7,10,20,68,72,20,40,40,62,2
